biOasis Announces Publication of Scientific Paper -- Transcend-Based Anti-Cancer Antibody BT2111 Crosses the Blood-Brain Barrier and Shows Efficacy in the Treatment of Metastatic HER2+ Breast Cancer Tumors in the Brains of Animal Model

VANCOUVER, BC--(Marketwired - August 29, 2016) - BIOASIS TECHNOLOGIES INC. (OTCQB: BIOAF) (TSX VENTURE: BTI), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier (BBB), today announced the publication of a peer-reviewed scientific paper detailing the results of an in-vivo study of the treatment of Metastatic HER2+ Breast Cancer brain tumors in an animal model using BT2111, biOasis's Trastuzumab-Melanotransferrin (Transcend) Conjugate.

The paper, entitled, "Anti-cancer Antibody Trastuzumab-Melanotransferrin Conjugate (BT2111) for the Treatment of Metastatic HER2+ Breast Cancer Tumors in the Brain: An In-Vivo Study," was published in Pharmaceutical Research, an official Journal of the American Association of Pharmaceutical Scientists. (Citation: Nounou, M.I., Adkins, C.E., Rubinchik, E. et al. Pharm Res (2016). doi:10.1007/s11095-016-2015-0)

The results detailed in the paper are from studies performed under the direction of Dr. Paul Lockman at Texas Tech University Health Sciences Center School of Pharmacy. In the study it was shown that the biOasis Transcend-Trastuzumab (Herceptin®) conjugate, BT2111, reduced the number of metastatic human HER2+ breast cancer tumors in the brains of test animals by 68% compared to control animals. Tumors that remained after treatment were 57% to 60% smaller than those in the control animals. In contrast, neither the administration of Trastuzumab alone nor hMTf (Transcend) alone was accompanied by a reduction in brain tumor number or size.

In the final paragraph of the paper's "Results" section, the authors state, "The results presented in this study provide evidence that BT2111 has efficacy in treating brain metastasis in preclinical models and validates the role hMTf has as a vector (Transcend vector platform) for the transport of antibodies across the BBB. This study has shown that Transcend can deliver Herceptin®, a chemotherapeutic used to treat HER2-positive breast cancer, in sufficient quantity to the brain to significantly reduce the number of HER2-positive metastatic brain tumors. The ability to more effectively permeate both the blood-brain and the blood-tumor barrier opens the door for the creation of new drugs designed to treat a wide variety of neurological diseases and disorders. Additionally, Transcend vector platform offers the potential to take existing clinically approved drugs that are near their end of patent life and extend them."